Compare Stocks: INDP, GERN, WVE, and CADL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CADL Candel Therapeutics	$11.57 -4.9%	$11.11	$4.35 ▼ $14.00	$886.48M	-0.48	1.49 million shs	603,937 shs
GERN Geron	$1.38 -1.8%	$1.48	$1.04 ▼ $2.01	$883.40M	0.61	14.34 million shs	2.49 million shs
INDP Indaptus Therapeutics	$2.52 +21.2%	$1.76	$0.92 ▼ $8.57	$336.43M	1.17	594,752 shs	1.93 million shs
WVE WAVE Life Sciences	$4.69 -2.6%	$5.58	$4.63 ▼ $21.73	$921.21M	-1.3	3.83 million shs	1.13 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CADL Candel Therapeutics	-3.41%	-7.80%	+15.90%	+49.14%	+144.87%
GERN Geron	-7.28%	-11.95%	-5.41%	+23.35%	+2.94%
INDP Indaptus Therapeutics	+12.43%	+77.78%	+74.79%	-41.74%	-22.68%
WVE WAVE Life Sciences	-2.04%	-1.43%	-20.76%	-17.21%	-35.70%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CADL Candel Therapeutics	$11.57 -4.9%	$11.11	$4.35 ▼ $14.00	$886.48M	-0.48	1.49 million shs	603,937 shs
GERN Geron	$1.38 -1.8%	$1.48	$1.04 ▼ $2.01	$883.40M	0.61	14.34 million shs	2.49 million shs
INDP Indaptus Therapeutics	$2.52 +21.2%	$1.76	$0.92 ▼ $8.57	$336.43M	1.17	594,752 shs	1.93 million shs
WVE WAVE Life Sciences	$4.69 -2.6%	$5.58	$4.63 ▼ $21.73	$921.21M	-1.3	3.83 million shs	1.13 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CADL Candel Therapeutics	-3.41%	-7.80%	+15.90%	+49.14%	+144.87%
GERN Geron	-7.28%	-11.95%	-5.41%	+23.35%	+2.94%
INDP Indaptus Therapeutics	+12.43%	+77.78%	+74.79%	-41.74%	-22.68%
WVE WAVE Life Sciences	-2.04%	-1.43%	-20.76%	-17.21%	-35.70%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CADL Candel Therapeutics	2.64	Moderate Buy	$19.29	58.47% Upside
GERN Geron	2.20	Hold	$4.00	185.71% Upside
INDP Indaptus Therapeutics	1.00	Sell	N/A	N/A
WVE WAVE Life Sciences	2.81	Moderate Buy	$22.31	363.88% Upside

Current Analyst Ratings Breakdown

Latest INDP, GERN, WVE, and CADL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2026	WVE WAVE Life Sciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/17/2026	CADL Candel Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/14/2026	CADL Candel Therapeutics	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$9.00 ➝ $12.00
8/13/2026	CADL Candel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$23.00
8/11/2026	GERN Geron	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/4/2026	WVE WAVE Life Sciences	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$27.00 ➝ $23.00
8/3/2026	WVE WAVE Life Sciences	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$13.00
8/3/2026	WVE WAVE Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/31/2026	WVE WAVE Life Sciences	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$31.00 ➝ $22.00
7/31/2026	WVE WAVE Life Sciences	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$24.00 ➝ $19.00
7/31/2026	WVE WAVE Life Sciences	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$15.00 ➝ $12.00

(Data available from 9/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	$0.95 per share	N/A
GERN Geron	$204.56M	4.40	N/A	N/A	$0.35 per share	4.00
INDP Indaptus Therapeutics	N/A	N/A	N/A	N/A	$1.40 per share	N/A
WVE WAVE Life Sciences	$42.73M	22.18	N/A	N/A	$3.10 per share	1.55

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CADL Candel Therapeutics	-$38.18M	-$1.41	N/A	N/A	N/A	N/A	-76.98%	-48.50%	11/12/2026 (Estimated)
GERN Geron	-$83.50M	-$0.11	N/A	23.33	N/A	-34.17%	-24.48%	-10.30%	11/4/2026 (Estimated)
INDP Indaptus Therapeutics	-$20.85M	-$6.33	N/A	N/A	N/A	N/A	-302.89%	-203.49%	11/17/2026 (Estimated)
WVE WAVE Life Sciences	-$204.38M	-$1.09	N/A	N/A	N/A	-309.73%	-50.36%	-40.06%	11/9/2026 (Estimated)

Latest INDP, GERN, WVE, and CADL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CADL Candel Therapeutics	-$0.2379	-$0.52	-$0.2821	-$0.52	N/A	N/A
8/13/2026	Q2 2026	INDP Indaptus Therapeutics	-$1.57	-$0.02	+$1.55	-$0.02	N/A	N/A
8/5/2026	Q2 2026	GERN Geron	-$0.0089	-$0.02	-$0.0111	-$0.02	$55.30 million	$57.48 million
7/30/2026	Q2 2026	WVE WAVE Life Sciences	-$0.2998	-$0.34	-$0.0403	-$0.34	$7.45 million	$2.27 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	N/A
GERN Geron	N/A	N/A	N/A	N/A	N/A
INDP Indaptus Therapeutics	N/A	N/A	N/A	N/A	N/A
WVE WAVE Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CADL Candel Therapeutics	0.38	16.09	16.09
GERN Geron	0.55	6.91	5.16
INDP Indaptus Therapeutics	N/A	19.49	19.49
WVE WAVE Life Sciences	N/A	9.99	9.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CADL Candel Therapeutics	13.93%
GERN Geron	73.71%
INDP Indaptus Therapeutics	7.06%
WVE WAVE Life Sciences	89.73%

Insider Ownership

Company	Insider Ownership
CADL Candel Therapeutics	14.30%
GERN Geron	1.71%
INDP Indaptus Therapeutics	9.94%
WVE WAVE Life Sciences	24.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CADL Candel Therapeutics	60	76.52 million	65.58 million	Optionable
GERN Geron	70	642.47 million	631.49 million	Optionable
INDP Indaptus Therapeutics	6	133.24 million	120.00 million	Not Optionable
WVE WAVE Life Sciences	240	197.05 million	149.17 million	Optionable

INDP, GERN, WVE, and CADL Headlines

Recent News About These Companies

WAVE Life Sciences (NASDAQ:WVE) Hits New 12-Month Low - Here's What Happened

1 hour ago | marketbeat.com

WAVE Life Sciences Ltd. $WVE Stock Holdings Boosted by Squarepoint Ops LLC

September 10 at 5:21 AM | marketbeat.com

Readystate Asset Management LP Purchases New Shares in WAVE Life Sciences Ltd. $WVE

September 7 at 5:51 AM | marketbeat.com

WAVE Life Sciences Ltd. (NASDAQ:WVE) Receives Consensus Rating of "Moderate Buy" from Analysts

September 4, 2026 | americanbankingnews.com

WAVE Life Sciences Ltd. (NASDAQ:WVE) Receives Average Recommendation of "Moderate Buy" from Analysts

September 4, 2026 | marketbeat.com

Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference

September 3, 2026 | globenewswire.com

WAVE Life Sciences (NASDAQ:WVE) Stock Price Down 4.3% - Time to Sell?

September 2, 2026 | marketbeat.com

WAVE Life Sciences (NASDAQ:WVE) Reaches New 12-Month Low - What's Next?

August 31, 2026 | marketbeat.com

WAVE Life Sciences (NASDAQ:WVE) Downgraded by Zacks Research to "Hold"

August 21, 2026 | marketbeat.com

WAVE Life Sciences (NASDAQ:WVE) Director Sells $23,222.64 in Stock

August 14, 2026 | insidertrades.com

Ken Takanashi Sells 3,864 Shares of WAVE Life Sciences (NASDAQ:WVE) Stock

August 13, 2026 | marketbeat.com

Insider Selling: WAVE Life Sciences (NASDAQ:WVE) Director Sells $42,070.00 in Stock

August 13, 2026 | marketbeat.com

WAVE Life Sciences (NASDAQ:WVE) Director Adrian Rawcliffe Sells 12,700 Shares

August 13, 2026 | marketbeat.com

Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover

August 13, 2026 | 247wallst.com

Wave Life Sciences: An Fairly Valued RNA Opportunity

August 12, 2026 | seekingalpha.com

WAVE Life Sciences (NASDAQ:WVE) Hits New 52-Week Low - Here's What Happened

August 12, 2026 | marketbeat.com

Wave Life Sciences Ltd. (WVE) Presents at Bank of America SMID Cap Virtual Conference Transcript

August 11, 2026 | seekingalpha.com

WAVE Life Sciences (NASDAQ:WVE) Stock Price Down 6.8% - Should You Sell?

August 11, 2026 | marketbeat.com

Wave Life Sciences Completes Redomiciliation to Delaware

August 10, 2026 | finance.yahoo.com

Wave Life Sciences Announces Completion of Redomiciliation to Delaware

August 10, 2026 | globenewswire.com

Did U.S. Redomiciliation and Mixed 1H 2026 Results Just Shift Wave Life Sciences' (WVE) Investment Narrative?

August 7, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

INDP, GERN, WVE, and CADL Company Descriptions

Candel Therapeutics NASDAQ:CADL

$11.57 -0.60 (-4.90%)

As of 12:11 PM Eastern

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Geron NASDAQ:GERN

$1.38 -0.03 (-1.79%)

As of 12:11 PM Eastern

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Indaptus Therapeutics NASDAQ:INDP

$2.52 +0.44 (+21.15%)

As of 12:10 PM Eastern

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

WAVE Life Sciences NASDAQ:WVE

$4.68 -0.13 (-2.60%)

As of 12:11 PM Eastern

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INDP, GERN, WVE, and CADL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INDP, GERN, WVE, and CADL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INDP, GERN, WVE, and CADL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

INDP, GERN, WVE, and CADL Company Descriptions

Candel Therapeutics NASDAQ:CADL

Geron NASDAQ:GERN

Indaptus Therapeutics NASDAQ:INDP

WAVE Life Sciences NASDAQ:WVE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INDP, GERN, WVE, and CADL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INDP, GERN, WVE, and CADL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INDP, GERN, WVE, and CADL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

INDP, GERN, WVE, and CADL Company Descriptions

Candel Therapeutics NASDAQ:CADL

Geron NASDAQ:GERN

Indaptus Therapeutics NASDAQ:INDP

WAVE Life Sciences NASDAQ:WVE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools